Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...
Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Monica Seles, the former tennis star, has experienced a couple of rare misfortunes in her life. In April 1993, Seles was ...
Temple University is granted summary judgment on the ADA retaliation claim of an assistant professor suffering from myasthenia gravis who was denied tenure, because the discrimination complaint he ...
The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene ...
World Myasthenia Gravis Day is celebrated every June 15 th. Myasthenia gravis (MG) is an autoimmune illness that affects approximately 1.5 to 2 million people globally. The disorder is characterized ...
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...
Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.
VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback